Abstract
Maraviroc, a CCR5 antagonist, is effective in treatment-experienced patients with R5-tropic HIV (JW AIDS Clin Care Sep 10 2007). In a manufacturer-funded trial, researchers assessed maraviroc’s safety and efficacy in patients with dual- or mixed-tropic virus (simply called “non-R5 virus”), viral loads ≥5000 copies/mL, and documented resistance to at least two classes of antiretroviral therapy (ART) or at …
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
